The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index; none of the 16 sources its claims cite is checked for support yet.
Adrenergic Mechanisms for the Effects of Epinephrine on Glucose Production and Clearance in Man
Open accessAbstract
THE PRESENT STUDIES WERE UNDERTAKEN TO ASSESS THE ADRENERGIC MECHANISMS BY WHICH EPINEPHRINE STIMULATES GLUCOSE PRODUCTION AND SUPPRESSES GLUCOSE CLEARANCE IN MAN: epinephrine (50 ng/kg per min) was infused for 180 min alone and during either alpha (phentolamine) or beta (propranolol)-adrenergic blockade in normal subjects under conditions in which plasma insulin, glucagon, and glucose were maintained at comparable levels by infusion of somatostatin (100 mug/h), insulin (0.2 mU/kg per min), and variable amounts of glucose. In additional experiments, to control for the effects of the hyperglycemia caused by epinephrine, variable amounts of glucose without epinephrine were infused along with somatostatin and insulin to produce hyperglycemia comparable with that observed during infusion of epinephrine. This glucose infusion suppressed glucose production from basal rates of 1.8+/-0.1 to 0.0+/-0.1 mg/kg per min (P < 0.01), but did not alter glucose clearance. During infusion of epinephrine, glucose production increased transiently from a basal rate of 1.8+/-0.1 to a maximum of 3.0+/-0.2 mg/kg per min (P < 0.01) at min 30, and returned to near basal rates at min 180 (1.9+/-0.1 mg/kg per min). Glucose clearance decreased from a basal rate of 2.0+/-0.1 to 1.5+/-0.2 ml/kg per min at the end of the epinephrine infusion (P < 0.01). Infusion of phentolamine did not alter these effects of epinephrine on glucose production and clearance. In contrast, infusion of propranolol completely prevented the suppression of glucose clearance by epinephrine, and inhibited the stimulation of glucose production by epinephrine by 80+/-6% (P < 0.001). These results indicate that, under conditions in which plasma glucose, insulin, and glucagon are maintained constant, epinephrine stimulates glucose production and inhibits glucose clearance in man predominantly by beta adrenergic mechanisms.
Overview
CoChat Summary
TL;DR
In normal human subjects with plasma insulin, glucagon, and glucose clamped, epinephrine increased endogenous glucose production transiently and decreased glucose clearance. These effects were predominantly mediated by beta-adrenergic mechanisms, since propranolol largely blocked them while phentolamine did not.
Key findings
- Epinephrine infusion increased endogenous glucose production from a basal rate of 1.8±0.1 to a maximum of 3.0±0.2 mg/kg per min at min 30, then returned to near basal values (1.9±0.1 mg/kg per min) at min 180; glucose clearance decreased from 2.0±0.1 to 1.5±0.1 ml/kg per min from 90 through 180 min (P < 0.01 vs. basal).
- Glucose infusion alone, producing comparable hyperglycemia without epinephrine, suppressed endogenous glucose production from 1.8±0.1 to 0.0±0.1 mg/kg per min (P < 0.01) but did not alter glucose clearance.
- Propranolol completely prevented the suppression of glucose clearance by epinephrine and inhibited epinephrine-stimulated glucose production by 80±6% (P < 0.001).
- Phentolamine did not significantly alter epinephrine’s effects on glucose production or clearance; the authors conclude that epinephrine stimulates glucose production and suppresses glucose clearance predominantly by beta-adrenergic mechanisms.
Methods
- Four protocols were performed in five healthy female adult volunteers aged 19–21 yr; all subjects completed protocols A, B, and C, and four completed protocol D.
- Somatostatin (100 μg/h), insulin (0.2 mU/kg per min), and variable glucose were infused to maintain comparable plasma insulin, glucagon, and glucose levels; epinephrine (50 ng/kg per min) was infused alone or with propranolol or phentolamine.
- Glucose kinetics were measured with [3-3H]glucose using Steele et al. equations as modified by DeBodo et al.; endogenous glucose production was calculated by subtracting exogenous glucose infusion, and glucose clearance was glucose disappearance divided by plasma glucose. Statistical analysis used two-tailed paired t tests on data from the stable clamp interval 90–180 min.
Limitations
- The authors state that the studies do not identify the tissues whose glucose clearance was affected by epinephrine or whether the effects were due to direct action on those tissues.
- The authors state that incomplete reversal of epinephrine-stimulated glucose production by propranolol could indicate a 20% alpha-adrenergic contribution or incomplete beta-adrenergic blockade; they favor incomplete beta blockade, partly because alpha blockade had no measurable effect.
- The authors note that plasma epinephrine rose about threefold higher during epinephrine plus propranolol than during epinephrine alone, suggesting beta blockade reduces epinephrine clearance; they state this may explain the failure of beta blockade to completely block glucose production.
- Evident from the text: the sample was very small (five healthy young women, four in one protocol), all subjects were female and within 10% of ideal body weight, and the findings may not generalize to other populations or disease states.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 11 Not checked · 35 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, plasma epinephrine concentrations, when epinephrine was infused along with propranolol (2,142±137 pg/ml), were approximately threefold greater than those observed when epinephrine was infused without propranolol (P < 0.001).”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This glucose infusion suppressed glucose production from basal rates of 1.8±0.1 to 0.0±0.1 mg/kg per min (P < 0.01)”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infusion of epinephrine at a rate of 50 ng/kg per min increased plasma epinephrine from a basal concentration of 26±4 pg/ml to levels averaging 882±60 pg/ml, from 90 through 180 min.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but did not alter glucose clearance.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Endogenous glucose production decreased from a basal rate of 1.8±0.1 to 0.4±0.1 mg/kg per min during the interval from 90 through 180 min (P < 0.001); this rate was significantly less than that observed over the same interval during infusion of epinephrine without propranolol (P < 0.001) and represented a 81±6% suppression of epinephrine-stimulated glucose production.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
21 more claims
Create a free account to see all 46 claims and every source verdict.
- It may state two separate claims as one. 7
- Probably not a substantial claim. 15
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Adrenergic Mechanisms for the Effects of Epinephrine on Glucose Production and Clearance in Man · p. 1
“returned to near basal rates at min 180 (1.9±0.1 mg/kg per min).”
§ RESULTS · p. 4
“then returned to approximately basal values (1.9±0.3 mg/kg per min) at min 180.”
Citations
Cites
Feinleib, M., & Zar, J. H. (1975) · Journal of the American Statistical Association · doi:10.2307/2285423 · Cited by 12,680
Zar, J. H. (1996) · Cited by 7,837
Coated Charcoal Immunoassay of Insulin
HERBERT, V., LAU, K.-S., GOTTLIEB, C. W., & BLEICHER, S. J. (1965) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-25-10-1375 · Cited by 2,968
Measurement of Size and Turnover Rate of Body Glucose Pool by the Isotope Dilution Method
Steele, R., Wall, J. S., de Bodo, R. C., & Altszuler, N. (1956) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1956.187.1.15 · Cited by 816
Randle, P., Newsholme, E., & Garland, P. (1964) · Biochemical Journal · doi:10.1042/bj0930652 · Cited by 736
Effects of arterial versus venous sampling on analysis of glucose kinetics in man
McGuire, E. A., Helderman, J. H., Tobin, J. D., Andres, R., & Berman, M. (1976) · Journal of Applied Physiology · doi:10.1152/jappl.1976.41.4.565 · Cited by 704
Epinephrine-induced insulin resistance in man
Deibert, D. C., & Defronzo, R. A. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109718 · Cited by 557
ON THE HORMONAL REGULATION OF CARBOHYDRATE METABOLISM; STUDIES WITH C14 GLUCOSE.
DeBodo, R. C., Steele, R., ALTSZULER, N., Dunn, A., & Bishop, J. (1963) · PubMed · Cited by 532
EFFECT OF EPINEPHRINE ON RAT DIAPHRAGM
Walaas, O., & Walaas, E. (1950) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)56223-2 · Cited by 410
A Receptor Mechanism for the Inhibition Of Insulin Release by Epinephrine in Man*
Porte, D. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105514 · Cited by 398
Cited by
Insulin Resistance in Essential Hypertension
Ferrannini, E., Buzzigoli, G., Bonadonna, R., Giorico, M. A., Oleggini, M., Graziadei, L., Pedrinelli, R., Brandi, L., & Bevilacqua, S. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708063170605 · Cited by 2,344
Assessment of Insulin Sensitivity in Vivo*
Bergman, R. N., Finegood, D. T., & Ader, M. (1985) · Endocrine Reviews · doi:10.1210/edrv-6-1-45 · Cited by 1,066
RIZZA, R. A., MANDARINO, L. J., & GERICH, J. E. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-54-1-131 · Cited by 696
Self-citationDose-response characteristics for effects of insulin on production and utilization of glucose in man
Rizza, R. A., Mandarino, L. J., & Gerich, J. E. (1981) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1981.240.6.e630 · Cited by 703
Self-citationPhysiology and Pathophysiology of the Human Sympathoadrenal Neuroendocrine System
Bleich, H. L., Moore, M. J., & Cryer, P. E. (1980) · New England Journal of Medicine · doi:10.1056/nejm198008213030806 · Cited by 652
Self-citation
Metadata
- Authors
- Rizza, R. A., Cryer, P. E., Haymond, M. W., & Gerich, J. E.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Haymond, M. W.
- Venue
- Journal of Clinical Investigation
- Published
- 1980-03-01
- Volume
- 65
- Issue
- 3
- Pages
- 682-689
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC371410
- OpenAlex
- W2103557599
- Cited by
- 340
- References
- 33
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 2 · 2020: 6 · 2018: 2 · 2017: 3 · 2016: 2 · 2015: 6 · 2014: 9 · 2013: 2 · 2012: 8
- FWCI
- 35.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Mayo Foundation for Medical Education and Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- epinephrine, glucose production, glucose clearance, beta-adrenergic receptors, alpha-adrenergic receptors, propranolol, phentolamine, adrenergic blockade, hyperglycemia, glucose infusion, insulin, glucagon, somatostatin
- MeSH terms
- Adult, Blood Glucose, Epinephrine, Glucagon, Humans, Hyperglycemia, Insulin, Male, Phentolamine, Propranolol, Receptors, Adrenergic, Receptors, Adrenergic, beta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adrenergic Mechanisms for the Effects of Epinephrine on Glucose Production and Clearance in Man. https://app.cochat.ai/papers/10.1172/jci109714
- The paper
- Rizza, R. A., Cryer, P. E., Haymond, M. W., & Gerich, J. E. (1980). Adrenergic Mechanisms for the Effects of Epinephrine on Glucose Production and Clearance in Man. Journal of Clinical Investigation. https://doi.org/10.1172/jci109714
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.